Radiant Biotherapeutics
Founded 2020 · Quebec, Canada corporation · 31 employees on LinkedIn · 5 known investors
Find your way into Radiant Biotherapeutics
Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
Founders & leadership
AF
Arthur FratamicoExecutive
DG
Deborah Geraghty, Ph.D.President and Chief Executive Officer
Investors · 5
FACIT (Fight Against Cancer Innovation Trust)Toronto · $1.1M
Toronto Innovation Acceleration PartnersToronto
Bill & Melinda Gates FoundationreportedSeattle
Also in the syndicate · 2
Amplitude VenturesleadGates Foundationlead
Funding
SEC filings, press & company announcements$34.3M disclosed across 1 of 2 rounds · 2024–2025
- Undisclosed amountSeries ANov 2025Source ↗
▶$34.3MraisedOct 2024 · 7 investors · BiotechnologyRule 506(b)
▶$34.3MraisedOct 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arthur FratamicoExecutive Officer, Promoter
- Offering amount
- $34.3M
- Amount sold
- $34.3M
- Minimum investment
- $500K
- First sale
- Aug 2024
- Incorporated
- Corporation, Quebec, Canada, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Octant Bio27 shared keywordsOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Aro Biotherapeutics19 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Bioworld16 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Radiant Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Radiant Biotherapeutics do?
- Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
- Who are Radiant Biotherapeutics's investors?
- Radiant Biotherapeutics's investors include FACIT (Fight Against Cancer Innovation Trust), Toronto Innovation Acceleration Partners, Bill & Melinda Gates Foundation.
- How much funding has Radiant Biotherapeutics raised?
- Radiant Biotherapeutics has disclosed $34.3M raised across 1 of its 2 known rounds.